|Bid||89.31 x 3200|
|Ask||89.32 x 800|
|Day's Range||88.89 - 89.50|
|52 Week Range||80.61 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.95|
|Expense Ratio (net)||0.13%|
Eli Lilly & Co. said its lower-priced Insulin Lispro Injection is now available for order in pharmacies, per vial or in a package of five KwikPens. The drug giant said Lispro Injection's list price is 50% lower than its identical branded Humalog U-100. Lispro Injection has a list price of $137.35 per vial and $265.20 for a package of five KwikPens. "Because most insurance plans provide affordable copays for chronic medicines that are much lower than list price, people should ask their pharmacist whether Insulin Lispro Injection or Humalog is the lower-cost option for them," Lilly said in a statement. The stock, which was still inactive in premarket trade, has edged up 0.7% year to date, while the SPDR Health Care Select Sector ETF has gained 3.1% and the S&P 500 has rallied 14.3%.
Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.
Shares of Becton Dickinson & Co. dropped 3.1% in morning trade Thursday, after the medical technology company topped fiscal second-quarter profit expectations, but slashed its full-year outlook, citing "recent regulatory and market pressures related to paclitaxel-coated devices." The net loss for the latest quarter narrowed to $18 million, or 7 cents a share, from $50 million, or 19 cents a share, in the same period a year ago. Adjusted EPS, which excludes non-recurring items, fell 2.3% to $2.59, but topped the FactSet consensus of $2.58. Revenue declined 0.6% to $4.195 billion, just shy of the FactSet consensus of $4.238 billion. For fiscal 2019, the company cut its adjusted EPS guidance range to $11.65 to $11.75 from $12.05 to $12.15. The company also lowered its revenue growth outlook to 8.0% to 9.0% from 8.5% to 9.5%, citing an estimated additional negative impact from currency moves. The stock has now slipped 0.1% year to date, while the SPDR Health Care Select Sector ETF has gained 2.3% and the S&P 500 has tacked on 13.8%.
The S&P 500 on Tuesday logged its steepest daily slide in about four months as investors reacted poorly to the prospect of escalating U.S.-China trade tensions.
S&P 500 earnings reported so far have come with an earnings beat that is second highest in five years. These sector ETFs should benefit from this trend.
Shares of Mallinckrodt PLC shot up 13% in premarket trade Tuesday, after the drug maker reported first-quarter earnings and sales that beat expectations, and raised its full-year outlook. The company swung to net income of $154.9 million, or $1.83 a share, from a loss of $18.0 million, or 21 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS rose 20% to $1.94, above the FactSet consensus of $1.70. Net sales rose 4.7% to $790.6 million, above the FactSet consensus of $766.3 million. Specialty brands sales fell 0.2% to $547.3 million but topped the FactSet consensus of $539.8 million, and specialty generics sales grew 18% to $243.3 million to beat expectations of $228.3 million. For 2019, the company raised its adjusted EPS guidance range to $8.30 to $8.60 from $8.10 to $8.40. The stock, which closed at a one-year low on May 1, has tumbled 21% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has edged up 1.0% and the S&P 500 has gained 8.4%.
Shares of UnitedHealth Group Inc. surged 3.1% in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, as the health care sector was one of the just 2 of the S&P 500's 11 sectors that are gaining ground. The Dow was down 128 points, with 23 of 30 components losing ground, while the SPDR Health Care Select Sector ETF edged up 0.2% with 25 of 62 components gaining ground. Earlier Monday, UnitedHealth disclosed that Chief Executive David Wichmann spent $904,366.88 to buy 20,000 of the company's stock at an average price of $231.7865 as early as Friday. The stock was now trading around $239.12.
Healthcare stocks have fallen somewhat out of favor, as tech and faster growing industries have lead the rally in equities this year. There is a prevailing notion that healthcare stocks are defensive, given their business models and the dividends they pay to their shareholders. However, there are standouts in the sector that are poised to deliver growth, spurred by new approvals and new markets.Source: Shutterstock For those looking for a diversified approach to investing in healthcare stocks, Health Care SPDR (NYSEARCA:XLV) and iShares Dow Jones US Healthcare (NYSEARCA:IYH) are good options that are relatively liquid. The two funds track each other very closely, though there is a slight difference between their yields. XLV yields 1.6%, while IYH has a slightly higher yield of 1.9%. * 7 Energy Stocks to Buy to Light Up Your Portfolio For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:ABBV) look like particularly good options. Within the XLV fund, MRK stock makes up 6% of overall holdings and ABBV stock accounts for 3.5% of its assets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMRK stock and ABBV stock are primed to bounce back after both dropped slightly recently. Their performance should help offset any potential weakness of the fund's other holdings, including Johnson & Johnson (NYSE:JNJ).JNJ stock is by far XLV's largest holding, comprising over 11% of its total assets. Though I have concerns about the legal risks facing JNJ stock, the benefit of owning the index is that its diversification reduces the risk posed by each stock. Healthcare Stocks to Buy: MRKMerck demonstrated its ability to execute on its global strategy in the first quarter, generating double-digit percentage sales and earnings per share growth, no small feat, considering that the market cap of MRK stock is over $200 billion. MRK's investments in research and development are clearly paying off, and the owners of MRK stock should be very positive about the company's 2019 outlook.The company's China business generated a large part of its growth, driven by high sales of its oncology drugs and vaccines there. Excluding the negative impact of currency fluctuations, its China sales soared 67% year-over-year. China is a huge market with significant demand, but it's not an easy nut to crack. Many multinational corporations spanning various industries have struggled to generate profits there. Merck's ability to drive sales in China bodes well for its future growth and for MRK stock.On the oncology front, the FDA's approval of MRK's Keytruda for a number of indications, including advanced renal cell carcinoma and melanoma with lymph nodes, was a big win for MRK stock. The EU also approved Keytruda in combination with chemotherapy. Sales of Keytruda were up 55% year-over-year in Q1.Expect further approvals of MRK's oncology drugs throughout the year to provide a boost to MRK stock. A number of the company's animal-health treatments could also be approved. Healthcare Stocks to Buy: ABBVABBV stock hasn't maintained as much upward momentum as I would have expected after it reported very solid Q1 results. This global pharmaceutical company focuses on four therapeutic areas: immunology, oncology, virology and neuroscience. ABBV is a healthcare stock that has a lot of potential, given the strength of the company's pipeline.ABBV's quarterly sales and earnings both beat expectations, leading ABBV to increase its full-year EPS guidance from $7.26 to $7.36. Most importantly, the company's pipeline advanced meaningfully. Notably, the FDAand the Japanese Ministry of Health, Labour and Welfare both approved the company's SKYRIZI treatment, which could improve the standard of care of psoriasis.Those were big wins in a therapeutic area with a great deal of long-term potential. ABBV has multiple other products making their way through the approval process, setting the stage for ABBV stock to benefit from multiple positive catalysts in the near future.In oncology, AbbVie announced a strategic partnership with Teneobio, a biotechnology company that's developing a new class of biologics for the treatment of cancer, autoimmunity and infectious diseases. The two companies have agreed to develop and commercialize a biologic calledTNB-383B for the potential treatment of multiple myeloma.ABBV' has several other ongoing collaborations that will expand its oncology research platform, enabling it to develop life-changing treatments andmeaningfully boost ABBV stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Stocks to Buy for May * 7 Stocks Worth Buying When They're Down * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post Two Healthcare Stocks in the XLV Fund Stand Out appeared first on InvestorPlace.
Declining sales of blockbuster drug Copaxone dragged down first-quarter revenue at Teva Pharmaceuticals Industries Ltd.
Investors wanting to stay ahead of the curve are wise to begin looking at the best exchange-traded funds to buy for a slowing economy. The best ETFs can help protect and diversify your portfolio.While the economy can be considered healthy on many counts, the GDP trend is clearly down. Depending upon which report you believe, the U.S. economy grew by about 3% in 2018. Growth was 4.2% in the second quarter of 2018, 3.4% in the third quarter and a 2.2% in the fourth quarter. The Federal Reserve expects GDP growth of 2.1% this year and 1.9% in 2020.The bottom line is that the economy is still growing but the pace of growth appears to be slowing. Now is not likely the best time to invest for recession, but it is a good time to tap down on risk while continuing to maintain exposure to the market. In different words, don't jump out of your stock funds and pile into cash. Just stay invested in a smarter way.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Stocks to Buy for May To make smarter moves for a slowing economy, these are the best ETFs to consider holding now: Best ETFs to Buy for a Slowing Economy: SPDR S&P 500 (SPY)Expenses: 0.0945%, or $9.45 for every $10,000 investedLong-term investors are wise to hold a low-cost stock fund like the SPDR S&P 500 (NYSEARCA:SPY), no matter what the economy and markets are doing.SPY is an outstanding core holding to build upon in your portfolio because of its primary quality as a diversified stock fund. But this same diversification is a key quality to look for in a fund when uncertainty abounds in the market.Since SPY tracks the S&P 500, you'll get exposure to approximately 500 of the largest U.S. companies, as measured (and weighted) by market cap. This means top holdings include mega-caps like Microsoft (NASDAQ:MSFT), Apple (NASDAQ:AAPL) and Amazon (NASDAQ:AMZN). Healthcare Select Sector SPDR (XLV)Expenses: 0.13%The healthcare sector can be a smart defensive play when the economy is weakening, and the Healthcare Select Sector SPDR (NYSEARCA:XLV) is just what the doctor ordered for this condition.No matter what the economy is doing, consumers still go to the doctor and fill their drug prescriptions. For this reason, healthcare stocks can hold up better than a broad market stock index when the investor herd begins to shift into risk-off mode. * 7 Stocks That Are Soaring This Earnings Season XLV gives investors a diversified basket of health stocks, primarily large U.S. names like Johnson & Johnson (NYSE:JNJ), UnitedHealth Group (NYSE:UNH) and Pfizer (NYSE:PFE). Utilities Select Sector SPDR (XLU)Expenses: 0.13%In addition to healthcare, the utilities sector is known for its defensive qualities, which makes an ETF like the Utilities Select Sector SPDR (NYSEARCA:XLU) a smart choice in a slowing economy.Utilities stocks are value-oriented investments, which tend to perform better than growth stocks as the economy gets closer to recession, especially when stocks enter a bear market.When the investor herd begins to turn away from the market risk of growth stocks, they like to buy the solid, dividend-producing stocks like XLU top holdings NextEra Energy (NYSE:NEE), Duke Energy (NYSE:DUK) and Dominion Energy (NYSE:D). Consumer Select Sector SPDR (XLP)Expenses: 0.13%Investors wanting broad exposure to defensive stocks will like what they see in the Consumer Select Sector SPDR (NYSEARCA:XLP).XLP tracks the Consumer Staples Select Sector index, which means it's full of defensive stocks in consumer industries and products such as beverages, household goods, food, and tobacco. Top holdings include Proctor & Gamble (NYSE:PG), Coca-Cola Company (NYSE:KO) and PepsiCo (NASDAQ:PEP). * 7 Stocks to Buy That Ought to Buy Back Shares XLP can compliment other defensive stock funds investing in the healthcare and utilities sectors because there is very little overlap with these sectors. SPDR Gold Shares (GLD)Expenses: 0.4%Investors wanting to build a defensive portfolio in anticipation of market volatility or a bear market may want to consider adding a low-cost precious metals fund like SPDR Gold Shares (NYSEARCA:GLD).Unlike mutual funds that invest in gold and other precious metals, GLD does not invest in mining stocks; it simply tracks the price of gold bullion, less expenses.Funds that track the price of gold can be great diversification tools because gold price movements have very little correlation with stock prices. Investors wanting to add GLD, or other funds with narrow concentrations in one sector or asset type, are wise to allocate 10% or less of their portfolio so they can receive the benefits of diversification without adding unnecessary market risk. iShares MSCI Emerging Markets (EEM)Expenses: 0.67%A slowing U.S. economy does not by default mean that economies elsewhere in the world are in trouble. If you want to diversify away from U.S. stocks, one of the best ETFs to do the job is the iShares MSCI Emerging Markets (NYSEARCA:EEM).EEM tracks the MSCI Emerging Markets Index, which consists of large- and mid-cap stocks, with the greatest concentration of exposure to emerging and developed Asia, including China, South Korea, Taiwan and India. * 7 A-Rated Stocks That Are Under $10 Most of the holdings in the EEM portfolio are large-caps like Tencent Holdings (OTCMKTS:TCEHY), Alibaba (NYSE:BABA) and Taiwan Semiconductor Manufacturing (NYSE:TSM). iShares Core U.S. Aggregate Bond (AGG)Expenses: 0.06%A slowing economy typically coincides with moderating or falling interest rates, which means bond prices can move higher. A cheap, diversified bond fund like the iShares Core U.S. Aggregate Bond Fund (NYSEARCA:AGG) is one of the best ETFs in this environment.AGG tracks the Bloomberg Barclays U.S. Aggregate Bond Index, which consists of over 7,000 bond securities, ranging from Treasuries to corporate bonds and municipal bonds of all maturities.Although long-term bonds can see higher price gains during recession, a slowing economy can be more challenging to navigate, which is why diversification is key for bond holdings, as well as stocks, in this environment.As of this writing, Kent Thune did not personally hold a position in any of the aforementioned securities. However, he holds SPY, XLV, XLP, GLD, and AGG in some client accounts. Under no circumstances does this information represent a recommendation to buy or sell securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Stocks to Buy for May * 5 Elephant-Sized Companies Warren Buffett Could Buy * 7 Cheap ETFs for Novice Investors Compare Brokers The post 7 of the Best ETFs to Buy for a Slowing Economy appeared first on InvestorPlace.
Investors in health-care stocks could be forgiven for asking: “What rally?” While the Dow Jones Industrial Average and the S&P 500 index have both soared more than 20% from their Christmas Eve lows, health-care stocks have gained less than half as much. As the S&P (SPX) sets new all-time highs and the Dow (DJIA) approaches its record, the Health Care Sector SPDR ETF (XLV) remains well below its own all-time closing high of $95.87 on Nov. 30. Behind health-care stocks’ underperformance is sheer panic at the emergence of Democratic presidential candidates like Senators Bernie Sanders, Elizabeth Warren and Kamala Harris, all of whom have called for some form of “Medicare for All” that would replace private medical insurance with single-payer coverage from the U.S. government.
Investors should consider sector-specific ETFs to focus on targeted segments of the market, especially as U.S. markets head in to the late business cycle. On the recent webcast, How Sectors Can Help with ...
Sectors can be an efficient tool to help advisors get a leg up on a changing market. In this upcoming webcast, gain insight on navigating sector investing in the late business cycle and how to best diversify ...
Shares of Eli Lilly & Co. dropped 3.0% in premarket trade Tuesday, after the drug giant reported first-quarter earnings that topped expectations, but revenue that missed, as key drugs Trulicity and Alimta fell short of forecasts. Net income rose to $4.24 billion, or $4.31 a share, from $1.22 billion, or $1.16 a share, in the same period a year ago. Excluding non-recurring items, such as gains from the sale of its Elanco Animal Health business, adjusted EPS rose to $1.33 from $1.31, and beat the FactSet consensus of $1.31. Revenue rose 3% to $5.09 billion, below the FactSet consensus of $5.20 billion. Among Lilly's top selling drugs, revenue for Trulicity rose 30% to $879.7 million but was below the FactSet consensus of $948.8 million; Humalog fell 8% to $730.8 million but beat expectations of $719.2 million; Alimta was virtually flat at $499.2 million, missing expectations of $568.6 million; Forteo was flat at $312.9 million, below expectations of $393.8 million; and Cialis dropped 38% to $308.2 million but beat expectations of $218.3 million. The company raised its 2019 adjusted EPS guidance to $5.60 to $5.70 from $5.55 to $5.65, and lowered its revenue outlook to reflect the Elanco disposition to $22.0 billion to $22.5 billion from $25.1 billion to $25.6 billion. The stock has gained 3.4% year to date through Monday, while the S&P 500 has advanced 17.4%.
DaVita Inc. said Monday Kent Thiry will step down as chief executive officer, after 20 years in the role, and transition to executive chairman. The kidney care services company said it named Javier Rodriguez, after it has named Javier Rodriguez as its new CEO, effective June 1. Rodriguez was previously CEO of the Kidney Care business since March 2014. DaVita's stock, which was still inactive in premarket trade, has gained 8.1% year to date, while the SPDR Health Care Select Sector ETF has edged up 2.9% and the S&P 500 has climbed 17.3%.
A proposal to expand Medicare and eliminate private insurance in the U.S. pummeled health care stocks recently. Portfolio Manager Andy Acker and Research Analyst Rich Carney explain what it means for investors. Key Takeaways A recent proposal to ...
Here’s what investors should look for on Thursday as these two pharmaceutical giants report first-quarter earnings.
Former Governor of Colorado and presidential hopeful John Hickenlooper discusses his thoughts on health care with Yahoo Finance’s Rick Newman.
Julian Emanuel, BTIG, on today's stunning stock reversal and whether now's the time to buy in. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Dan Nathan and Guy Adami.
Many Americans struggle with high health care costs, and they want help from Washington. But that doesn’t mean they’re willing to give up private insurance. A recent Kaiser Family Foundation survey of people with employer-provided insurance finds that 68% say their plan is excellent or good. One-quarter say their coverage is average, with only 6% rating their plan as poor or failing. Overall, 72% say they’re “grateful” for their coverage.